Nika Pharmaceuticals Reports Q2 2025 Financial Results with $18,381 Net Loss

Nika Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $18,381, a decrease from the $22,457 loss recorded in the same period of 2024. The company has not generated any revenue during this period, maintaining a consistent trend of operating at a loss. Total operating expenses for the quarter were $18,381, down from $22,457 in the previous year, primarily due to a reduction in professional fees, which fell to $4,081 from $14,957. General and administrative expenses increased to $14,300 from $7,500, reflecting ongoing costs associated with regulatory filings.

In terms of balance sheet performance, Nika Pharmaceuticals reported total assets of $31,607 as of June 30, 2025, significantly up from $17,934 at the end of 2024. This increase was largely driven by a rise in cash reserves, which grew to $15,616 from $2,083. However, the company also reported total liabilities of $284,164, up from $239,164, primarily due to amounts owed to related parties. The stockholders' deficit widened to $(252,557) from $(221,230), indicating ongoing financial challenges.

Strategically, Nika Pharmaceuticals has been active in expanding its operations and product offerings. The company completed a merger with Nika BioTechnology, Inc. in April 2024, which increased its ownership stake in Nika Europe, Ltd. to 80%. This merger is expected to enhance Nika's market presence in Europe, Asia, and Africa, as the company prepares to construct a pharmaceutical manufacturing facility. Additionally, Nika has entered into exclusive rights agreements for the production and distribution of various pharmaceutical products, including Thymus Nuclear Glycoprotein and dietary supplements.

Operationally, Nika Pharmaceuticals has not reported significant changes in customer counts or user statistics, as the company continues to focus on establishing its manufacturing capabilities. The company has not disclosed specific metrics regarding product adoption rates or market share figures. As of June 30, 2025, the company had a total of 1,026,406,001 shares of common stock outstanding, reflecting a slight increase from the previous quarter. The company’s management has indicated that it may seek additional capital through equity or debt offerings to support its operations and growth initiatives.

Looking ahead, Nika Pharmaceuticals faces substantial uncertainty regarding its ability to continue as a going concern, given its accumulated deficit of $8,958,938 and lack of revenue generation. The company is exploring potential merger opportunities with operating entities to fulfill its business plan. Management has acknowledged the risks associated with its current financial position and the need for strategic decisions to ensure future viability.